Table 1.
Cancer aptamers in clinical trials
| NCT number/phase | Title | Conditions | Interventions | Outcome measures | Locations |
|---|---|---|---|---|---|
| ClinicalTrials.gov: NCT03385148 early phase I | the clinical application of 68Ga-labeled ssDNA aptamer sgc8 in healthy volunteers and colorectal patients | colorectal cancer | drug: 68Ga-sgc8 | diagnostic efficacy | China |
| ClinicalTrials.gov: NCT02780011 phase I | alisertib (MLN8237) and brentuximab vedotin for relapsed/refractory CD30-positive lymphomas and solid malignancies | CD30-positive lymphoma; CD30-positive solid tumor | drug: brentuximab vedotin; drug: alisertib | MTD; DLTs; RP2D; antitumor activity; area under the plasma concentration versus time curve | USA |
| ClinicalTrials.gov: NCT02237183 phase I | iloprost in preventing lung cancer in former smokers | lung carcinoma | drug: iloprost; other: placebo administration; other: quality-of-life assessment; other: questionnaire administration; descriptive statistics for the effect on serum proteins as quantitated by aptamer-based analysis | incidence of clinical toxicity; treatment compliance; response of airway histology; serum protein profiling; endobronchial-brushing gene expression; gene expression of dysplastic lesions; improvement in chronic obstructive pulmonary disease (COPD); whether the in vitro response of cultured airway epithelial progenitor cells to iloprost is a predictor of in vivo response in study subjects | USA |
| ClinicalTrials.gov: NCT01034410 phase II | a study of AS1411 combined with cytarabine in the treatment of patients with primary refractory or relapsed acute myeloid leukemia | acute myeloid leukemia | drug: AS1411; drug: cytarabine | comparison of 40 and 80 mg/kg/day of AS1411 in combination with cytarabine therapy or cytarabine alone for response rate; duration of emission; disease-free survival; overall survival; hematological recovery; safety; PD and PK | Australia, China, New Zealand, Taiwan, USA |
| ClinicalTrials.gov: NCT01830244 phase II | IST neoadjuvant Abraxane in newly diagnosed breast cancer | breast cancer | drug: nab-paclitaxel; post-biopsy aptamer assessment | pathological complete response in the breast; pathologic response rate in breast and axillary lymph nodes; rate of pathologic complete response and near-complete response in the breast combined; breast conservation rate; progression-free survival; safety and tolerability | Australia |
| ClinicalTrials.gov: NCT04459468 | identify proteomic biomarkers for outcome prediction of Lipiodol TACE treatment | hepatocellular carcinoma | drug: Lipiodol | predictive accuracy of proteomic biomarker(s) for overall survival in hepatocellular carcinoma patients; predictive accuracy of proteomic biomarker(s) for progression-free survival in hepatocellular carcinoma patients | USA |
| ClinicalTrials.gov: NCT02957370 | molecular biosensors for detection of bladder cancer | urinary bladder neoplasms | urinary “fingerprint” for urinary bladder neoplasms |
DLT, dose-limiting toxicity; IST, immunosuppressive therapy; MTD, maximum-tolerated dose; PK, pharmacokinetics; PD, pharmacodynamics; RP2D, recommended phase 2 dose; ssDNA, single-stranded DNA; TACE, transarterial chemoembolization.